XXXX supplement use during @entity0 treatment and survival: a prospective cohort study.

@entity1 @entity0 @entity270 @entity5 @entity620 @entity2221 @entity204
BACKGROUND: Antioxidants may protect normal cells from the oxidative damage that occurs during radiotherapy and certain chemotherapy regimens; however, the same mechanism could protect @entity5 cells and potentially reduce effectiveness of @entity5 treatments. We evaluated the association of @entity2221 supplement use in the first 6 months after @entity0 treatment with total mortality and recurrence. METHODS: We conducted a population-based prospective cohort study of 4,877 @entity1 aged 20 to 75 years diagnosed with invasive @entity0 in Shanghai, China, between March 2002 and April 2006. @entity1 were interviewed approximately 6 months after diagnosis and followed up by in- @entity1 interviews and record linkage with the vital statistics registry. RESULTS: During a mean follow-up of 4.1 years, 444 @entity204 and 532 recurrences occurred. @entity2221 use shortly after @entity0 was associated with reduced mortality and recurrence risk, adjusted for multiple lifestyle factors, sociodemographics, and known clinical prognostic factors. @entity1 who used antioxidants ( @entity270 , @entity620 , multivitamins) had 18% reduced mortality risk (HR = 0.82, 95% CI: 0.65-1.02) and 22% reduced recurrence risk (HR = 0.78, 95% CI: 0.63-0.95). The inverse association was found regardless of whether @entity2221 use was concurrent or nonconcurrent with chemotherapy, but was present only among @entity1 who did not receive radiotherapy. CONCLUSIONS: @entity2221 supplement use in the first 6 months after @entity0 may be associated with reduced risk of mortality and recurrence. IMPACT: Our results do not support the current recommendation that @entity0 @entity1 should avoid use of @entity2221 supplements.
